A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Value in Health

• Publication date

  2018-02-01

• Fields of study

  Medicine, Computer Science, Economics

• Identifiers
  DOI 10.1016/j.jval.2017.12.009PMID 29477394
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

  2018cited by this paper
• An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].

  2018cited by this paper
• Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]

  2018cited by this paper
• Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].

  2018cited by this paper
• Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].

  2018cited by this paper
• A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].

  2018cited by this paper

• Multicriterio e valutazioni economiche: verso una proposta per un nuovo framework per il prezzo dei farmaci in Italia

  2026cites this paper
• Social framework to judge the importance of breast cancer.

  2025cites this paper
• From “Quality, Not Quantity” to “Quality as Quantity”: How the “Care Economy” Became Valuable

  2025cites this paper
• The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review

  2025cites this paper
• Economic evaluations of disease-modifying therapies for spinal muscular atrophy: a systematic literature review

  2025cites this paper
• Cost-Effectiveness in Critical Care: A Systematic Review of Empirical Evaluations

  2025cites this paper
• A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States.

  2025cites this paper
• New estimates of the costs of adverse events in patients with cancer

  2025cites this paper
• Value attributes of advanced therapy medicinal products: a comprehensive literature review

  2025cites this paper
• Overcoming the Blood–Brain Barrier: Advanced Strategies in Targeted Drug Delivery for Neurodegenerative Diseases

  2025cites this paper
• Developing economic evaluation guidelines for the Kingdom of Saudi Arabia: Engagement of local experts

  2025cites this paper
• Identifying Key Factors for Health Economic Development in Medical Sciences Universities: The Role of Accounting Information Systems

  2025cites this paper
• POST MARKET CLINICAL EVALUATION OF MEDICAL DEVICES INTEGRATING HEALTH ECONOMICS AND ARTIFICIAL INTELLIGENCE FOR IMPROVED OUTCOME.

  2025cites this paper
• Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics

  2025cites this paper
• Application of a Value Framework to Determine the Value of Prophylaxis Versus On-Demand Treatment in Adults with Hemophilia A in China

  2025cites this paper
• Consideration for Health Disparities in Value Assessment Frameworks

  2024cites this paper
• Economic Evaluations of Health Care Interventions in Pediatric Hospital Care.

  2024cites this paper
• Negotiating pricing and payment terms for insurance covered mHealth apps: a qualitative content analysis and taxonomy development based on a German experience

  2024cites this paper
• Cost-effectiveness of Risk Stratified Care vs Usual Care for Low Back Pain in the Military Health System.

  2024cites this paper
• The broader benefits of vaccines: methodologies for inclusion in economic evaluation

  2024cites this paper
• Randomized Controlled Trial Based US Commercial Payor Cost-Effectiveness Analysis of Endoscopic Sleeve Gastroplasty Versus Lifestyle Modification Alone for Adults With Class I/II Obesity

  2024cites this paper
• The Value of the QALY.

  2024cites this paper
• Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians

  2024cites this paper
• A Systematic Review of Value Criteria for Next-Generation Sequencing/Comprehensive Genomic Profiling to Inform Value Framework Development.

  2024cites this paper
• An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year

  2023cites this paper
• Evolving use of Health Technology Assessment in Medical Device Procurement - a Global Systematic Review: An ISPOR Special Interest Group Report.

  2023cites this paper
• Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.

  2023cites this paper
• How Much Better is Faster? Value Adjustments for Health-Improvement Sequences

  2023cites this paper
• Developing Criteria for Health Economic Quality Evaluation (CHEQUE) Tool.

  2023cites this paper
• The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework

  2023cites this paper
• Multi-Criteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next?

  2023cites this paper
• Multi-Stakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions.

  2023cites this paper
• Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications

  2023cites this paper
• The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis.

  2022cites this paper
• Promoting innovation while controlling cost: The UK's approach to health technology assessment.

  2022cites this paper
• Health technology assessment for gene therapies in haemophilia

  2022cites this paper
• Colonoscopy for Diagnostic Evaluation and Interventions to Prevent Recurrence After Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians

  2022cites this paper
• Diagnosis and Management of Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians

  2022cites this paper
• Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review

  2022cites this paper
• Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency.

  2022cites this paper
• Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast]

  2022cites this paper
• Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile

  2022cites this paper
• Does meta-analysis of economic evaluations have the potential to play a role in healthcare decision-making in the United States?

  2022cites this paper
• Considering Severity in Health Technology Assessment: Can We Do Better?

  2022cites this paper
• Performing Cost-Effectiveness Analyses to Support Policy Making

  2022cites this paper
• Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

  2022cites this paper
• What Role, if any, Should Economic Evaluation Play in Market Access Decisions of Pharmaceutical Treatments for Cancer Patients with Short Life Expectancy?

  2021influential citation
• Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach.

  2021cites this paper
• Prioritization and Refinement of Patient-Informed Value Elements as Attributes for Chronic Obstructive Pulmonary Disease Treatment Preferences

  2021cites this paper
• How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?

  2021cites this paper
• A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States

  2021cites this paper
• Implications of response shift for micro-, meso-, and macro-level healthcare decision-making using results of patient-reported outcome measures

  2021cites this paper
• Value assessment frameworks: who is valuing the care in healthcare?

  2021cites this paper
• Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions

  2021cites this paper
• Verifying the value of existing frameworks for formulary review at a large academic health system: assessing inter-rater reliability

  2021cites this paper
• The Role of Patient Experience in the Value Assessment of Complex Technologies - Do HTA Bodies Need to Reconsider How Value is Assessed?

  2021cites this paper
• Estimating optimal willingness to pay thresholds for cost-effectiveness analysis: A generalized method.

  2021cites this paper
• Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies.

  2021cites this paper
• Decision Rules in Cost-Utility Analysis of Health Technologies

  2021cites this paper
• How to Value Orphan Drugs? A Review of European Value Assessment Frameworks

  2021cites this paper
• Modelling the value of innovative treatments for Alzheimer’s disease in the United States

  2021cites this paper
• Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

  2021cites this paper
• Proposal for capturing patient experience through extended value frameworks of health technologies

  2021cites this paper
• Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making

  2021cites this paper
• Stakeholder point of view on prescription drug affordability - a systematic literature review and content analysis.

  2021cites this paper
• How Does Cost-Effectiveness Analysis Inform Health Care Decisions?

  2021cites this paper
• Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review.

  2021cites this paper
• Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic

  2021cites this paper
• What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks.

  2021cites this paper
• Estimating and Comparing Health and Financial Risk Protection Outcomes in Economic Evaluations.

  2021cites this paper
• Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.

  2021cites this paper
• Application of economic evidence in health technology assessment and decision-making for the allocation of health resources in Latin America: Seven key topics and a preliminary proposal for implementation

  2021cites this paper
• Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation.

  2020cites this paper
• Measuring clinical utility in the context of genetic testing: a scoping review

  2020cites this paper
• Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial

  2020cites this paper
• HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies

  2020cites this paper
• Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries—A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses

  2020cites this paper
• Stakeholder-Engaged Derivation of Patient-Informed Value Elements

  2020cites this paper
• Linked Pharmacometric‐Pharmacoeconomic Modeling and Simulation in Clinical Drug Development

  2020cites this paper
• Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy

  2020cites this paper
• Selecting Image-Guided Surgical Technologies in Oncology: A Surgeon's Perspective.

  2020cites this paper
• HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales

  2020cites this paper
• Chapter 1: Introduction to Pharmacoeconomics

  2020cites this paper
• Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies.

  2020cites this paper
• Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?

  2020cites this paper
• Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.

  2020cites this paper
• Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective.

  2020cites this paper
• Health Economics Tools and Precision Medicine: Opportunities and Challenges

  2020cites this paper
• Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.

  2020cites this paper
• SF-6D utility scores for alcohol use disorder status and alcohol consumption risk levels in the US population.

  2020cites this paper
• Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability

  2020cites this paper
• Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

  2020cites this paper
• Should health technology assessment be more patient centric? If so, how?

  2020cites this paper
• How Are Incremental Cost-Effectiveness, Contextual Considerations, and Other Benefits Viewed in Health Technology Assessment Recommendations in the United States?

  2020cites this paper
• An introduction to economic studies, health emergencies, and COVID‐19

  2020cites this paper
• Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework.

  2019cites this paper
• Valuing Health: Evolution, Revolution, Resistance, and Reform.

  2019cites this paper
• The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems

  2019cites this paper
• New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare-An Introduction.

  2019cites this paper
• The promise of Immuno-oncology: implications for defining the value of cancer treatment

  2019cites this paper